ARMP
Price
$3.83Alerts
Change
+$0.08 (+2.13%)
Updated
Nov 11, 04:59 PM (EDT)
Capitalization
130.51M
Earnings call today
Intraday BUY SELL Signals
JUNS
Price
$2.14Alerts
Change
-$0.08 (-3.60%)
Updated
Nov 11 closing price
Capitalization
2.9M
2 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARMP vs JUNS

ARMP vs JUNS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ARMP vs. JUNS commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARMP is a Hold and JUNS is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ARMP with price predictions
Nov 10, 2026

ARMP's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for ARMP turned positive on October 20, 2026. Looking at past instances where ARMP's MACD turned positive, the stock continued to rise in 42 of 46 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ARMP's RSI Indicator exited the oversold zone, 23 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on ARMP as a result. In 90 of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.

Following a +26.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARMP advanced for three days, in 218 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

ARMP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for ARMP entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.565) is normal, around the industry mean (3.498). P/E Ratio (-0.664) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.260) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. ARMP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for JUNS with price predictions
Nov 10, 2026

JUNS's Stochastic Oscillator is remaining in oversold zone for 14 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +18.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where JUNS advanced for three days, in 67 of 82 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

JUNS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 26, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on JUNS as a result. In 26 of 28 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The 50-day moving average for JUNS moved below the 200-day moving average on October 13, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JUNS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for JUNS entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-7.926) is normal, around the industry mean (3.498). P/E Ratio (-0.118) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (22.831) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. JUNS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JUNS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
ARMP: Fundamental Ratings
ARMP
OUTLOOK RATING
1..100
19
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
PROFIT vs RISK RATING
1..100
97
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
63
P/E GROWTH RATING
1..100
14
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ARMPJUNS
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 9 days ago
82%
Declines
ODDS (%)
Bearish Trend 14 days ago
87%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
75%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (ARMP: $3.75 vs. JUNS: $2.22)
Brand notoriety: ARMP and JUNS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARMP: 29% vs. JUNS: 12%
Market capitalization -- ARMP: $130.51M vs. JUNS: $2.9M
ARMP [@Biotechnology] is valued at $130.51M. JUNS’s [@Biotechnology] market capitalization is $2.9M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARMP’s FA Score shows that 1 FA rating(s) are green while JUNS’s FA Score has 1 green FA rating(s).

  • ARMP’s FA Score: 1 green, 4 red.
  • JUNS’s FA Score: 1 green, 4 red.
According to our system of comparison, ARMP is a better buy in the long-term than JUNS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARMP’s TA Score shows that 5 TA indicator(s) are bullish while JUNS’s TA Score has 3 bullish TA indicator(s).

  • ARMP’s TA Score: 5 bullish, 3 bearish.
  • JUNS’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, ARMP is a better buy in the short-term than JUNS.

Price Growth

ARMP (@Biotechnology) experienced а +21.36% price change this week, while JUNS (@Biotechnology) price change was -8.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

ARMP is expected to report earnings on Nov 11, 2026.

JUNS is expected to report earnings on Nov 13, 2026.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ARMP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARMP has been loosely correlated with RANI. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ARMP jumps, then RANI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARMP
1D Price
Change %
ARMP100%
-1.32%
RANI - ARMP
44%
Loosely correlated
-2.47%
DMRA - ARMP
34%
Loosely correlated
+0.33%
SION - ARMP
32%
Poorly correlated
+3.64%
JANX - ARMP
31%
Poorly correlated
-5.64%
ARTV - ARMP
30%
Poorly correlated
-3.79%
More

JUNS and

Correlation & Price change

A.I.dvisor tells us that JUNS and ARMP have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that JUNS and ARMP's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JUNS
1D Price
Change %
JUNS100%
+0.91%
ARMP - JUNS
27%
Poorly correlated
-1.32%
DNA - JUNS
24%
Poorly correlated
-2.91%
NAGE - JUNS
23%
Poorly correlated
-5.70%
KZIA - JUNS
22%
Poorly correlated
-0.13%
RXRX - JUNS
22%
Poorly correlated
-6.70%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
RUNN35.800.04
+0.12%
Running Oak Efficient Growth ETF (RUNN)
PWB143.27-0.32
-0.22%
Invesco Large Cap Growth ETF (PWB)
VEFA81.02-0.30
-0.37%
VanEck MSCI EAFE Analyst Sentiment ETF (VEFA)
XPND35.97-0.15
-0.41%
First Trust Expanded Technology ETF (XPND)
PCF4.98-0.07
-1.39%
High Income Securities Fund